Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Introduction: Although amyloid β peptide (Aβ) is cleared from the brain to cerebrospinal fluid and the peripheral circulation, mechanisms for its removal from blood remain unresolved. Primates have uniquely evolved a highly effective peripheral clearance mechanism for pathogens, immune adherence, in which erythrocyte complement receptor 1 (CR1) plays a major role. Methods: Multidisciplinary methods were used to demonstrate immune adherence capture of Aβ by erythrocytes and its deficiency in Alzheimer's disease (AD). Results: Aβ was shown to be subject to immune adherence at every step in the pathway. Aβ dose‐dependently activated serum complement. Complement‐opsonized Aβ was captured by erythrocytes via CR1. Erythrocytes, Aβ, and hepatic Kupffer cells were colocalized in the human liver. Significant deficits in erythrocyte Aβ levels were found in AD and mild cognitive impairment patients. Discussion: CR1 polymorphisms elevate AD risk, and >80% of human CR1 is vested in erythrocytes to subserve immune adherence. The present results suggest that this pathway is pathophysiologically relevant in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,611
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease
Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582
Grammas, P. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-26 · Cited by 432
Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., & Tenner, A. J. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.10.5050 · Cited by 330 · cited 2×
“However, both our research [15,16] and that of others [14,17] have shown that Ab, like certain bacterial and viral antigens [13], does not require immune complex formation to activate complement or to be bound by complement opsonins that serve as ligands for immune adherence.”
BackgroundResultSelf-citationExpression of Novel Alzheimer’s Disease Risk Genes in Control and Alzheimer’s Disease Brains
Karch, C. M., Jeng, A. T., Nowotny, P., Cady, J., Cruchaga, C., & Goate, A. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050976 · Cited by 328
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“As such, circulating endogenous anti-Ab antibodies, which are common in human subjects [44–48], and anti-Ab antibodies introduced by immunotherapy, as reviewed in [49], should theoretically enhance complement activation and peripheral clearance of Ab.”
Background
Cited by
Wen, Y., Lambrecht, J., Ju, C., & Tacke, F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00558-8 · Cited by 695
The good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Self-citationComplement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
“ance is the mechanism by which the rs6656401 SNP impacts AD pathology [70].”
BackgroundErythropoietin signaling in peripheral macrophages is required for systemic β‐amyloid clearance
Xu, L., Li, L., Pan, C., Song, J., Zhang, C., Wu, X., Hu, F., Liu, X., Zhang, Z., & Zhang, Z. (2022) · The EMBO Journal · doi:10.15252/embj.2022111038 · Cited by 29
Metadata
- Authors
- Brubaker, W. D., Crane, A., Johansson, J. U., Yen, K., Garfinkel, K., Mastroeni, D., Asok, P., Bradt, B., Sabbagh, M., Wallace, T. L., Glavis‐Bloom, C., Tenner, A. J., & Rogers, J.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-05-02
- Volume
- 13
- Issue
- 12
- Pages
- 1397-1409
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W2610365490
- Cited by
- 53
- References
- 16
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms. https://app.cochat.ai/papers/10.1016/j.jalz.2017.03.010
- The paper
- Brubaker, W. D., Crane, A., Johansson, J. U., Yen, K., Garfinkel, K., Mastroeni, D., Asok, P., Bradt, B., Sabbagh, M., Wallace, T. L., Glavis‐Bloom, C., Tenner, A. J., & Rogers, J. (2017). Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2017.03.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.